145 related articles for article (PubMed ID: 23434414)
21. The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze.
Akbari E; Naghdi N; Motamedi F
Peptides; 2007 Mar; 28(3):650-6. PubMed ID: 17161886
[TBL] [Abstract][Full Text] [Related]
22. 2-Methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides: a new class of selective orexin 2 antagonists.
Micheli F; Antolini M; Di Fabio R; Pellacani A; Pozzan A
Bioorg Med Chem Lett; 2010 Nov; 20(22):6405-7. PubMed ID: 20933413
[TBL] [Abstract][Full Text] [Related]
23. Enantioselective synthesis of a dual orexin receptor antagonist.
Mangion IK; Sherry BD; Yin J; Fleitz FJ
Org Lett; 2012 Jul; 14(13):3458-61. PubMed ID: 22725839
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats.
Whitman DB; Cox CD; Breslin MJ; Brashear KM; Schreier JD; Bogusky MJ; Bednar RA; Lemaire W; Bruno JG; Hartman GD; Reiss DR; Harrell CM; Kraus RL; Li Y; Garson SL; Doran SM; Prueksaritanont T; Li C; Winrow CJ; Koblan KS; Renger JJ; Coleman PJ
ChemMedChem; 2009 Jul; 4(7):1069-74. PubMed ID: 19418500
[TBL] [Abstract][Full Text] [Related]
25. Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists.
Tran DT; Bonaventure P; Hack M; Mirzadegan T; Dvorak C; Letavic M; Carruthers N; Lovenberg T; Sutton SW
Eur J Pharmacol; 2011 Sep; 667(1-3):120-8. PubMed ID: 21679703
[TBL] [Abstract][Full Text] [Related]
26. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
27. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA).
Malherbe P; Roche O; Marcuz A; Kratzeisen C; Wettstein JG; Bissantz C
Mol Pharmacol; 2010 Jul; 78(1):81-93. PubMed ID: 20404073
[TBL] [Abstract][Full Text] [Related]
28. Orexin receptor antagonists: a review of promising compounds patented since 2006.
Coleman PJ; Renger JJ
Expert Opin Ther Pat; 2010 Mar; 20(3):307-24. PubMed ID: 20180618
[TBL] [Abstract][Full Text] [Related]
29. The discovery of potent antagonists of NPBWR1 (GPR7).
Anthony Romero F; Hastings NB; Moningka R; Guo Z; Wang M; Di Salvo J; Lei Y; Trusca D; Deng Q; Tong V; Terebetski JL; Ball RG; Ujjainwalla F
Bioorg Med Chem Lett; 2012 Jan; 22(2):1014-8. PubMed ID: 22197390
[TBL] [Abstract][Full Text] [Related]
30. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ
J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists.
Dowling JE; Vessels JT; Haque S; Chang HX; van Vloten K; Kumaravel G; Engber T; Jin X; Phadke D; Wang J; Ayyub E; Petter RC
Bioorg Med Chem Lett; 2005 Nov; 15(21):4809-13. PubMed ID: 16153830
[TBL] [Abstract][Full Text] [Related]
32. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.
Coleman PJ; Cox CD; Roecker AJ
Curr Top Med Chem; 2011; 11(6):696-725. PubMed ID: 21261591
[TBL] [Abstract][Full Text] [Related]
33. Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans.
Dingemanse J; Hoever P; Hoch M; Treiber A; Wagner-Redeker W; Miraval T; Hopfgartner G; Shakeri-Nejad K
Drug Metab Dispos; 2013 May; 41(5):1046-59. PubMed ID: 23431113
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists.
Coleman PJ; Schreier JD; McGaughey GB; Bogusky MJ; Cox CD; Hartman GD; Ball RG; Harrell CM; Reiss DR; Prueksaritanont T; Winrow CJ; Renger JJ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2311-5. PubMed ID: 20207138
[TBL] [Abstract][Full Text] [Related]
35. Expression of orexin receptors 1 (OX1R) and 2 (OX2R) in the porcine pituitary during the oestrous cycle.
Kaminski T; Smolinska N; Nitkiewicz A; Przala J
Anim Reprod Sci; 2010 Jan; 117(1-2):111-8. PubMed ID: 19394166
[TBL] [Abstract][Full Text] [Related]
36. Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists.
Jiang R; Song X; Bali P; Smith A; Bayona CR; Lin L; Cameron MD; McDonald PH; Kenny PJ; Kamenecka TM
Bioorg Med Chem Lett; 2012 Jun; 22(12):3890-4. PubMed ID: 22617492
[TBL] [Abstract][Full Text] [Related]
37. Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.
Arban R; Bianchi F; Buson A; Cremonesi S; Di Fabio R; Gentile G; Micheli F; Pasquarello A; Pozzan A; Tarsi L; Terreni S; Tonelli F
Bioorg Med Chem Lett; 2010 Sep; 20(17):5044-9. PubMed ID: 20674355
[TBL] [Abstract][Full Text] [Related]
38. Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding.
Cox CD; McGaughey GB; Bogusky MJ; Whitman DB; Ball RG; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2009 Jun; 19(11):2997-3001. PubMed ID: 19406641
[TBL] [Abstract][Full Text] [Related]
39. Biomedical application of orexin/hypocretin receptor ligands in neuroscience.
Boss C; Brisbare-Roch C; Jenck F
J Med Chem; 2009 Feb; 52(4):891-903. PubMed ID: 19199652
[No Abstract] [Full Text] [Related]
40. Synthesis of (3,4-dimethoxyphenoxy)alkylamino acetamides as orexin-2 receptor antagonists.
Cole AG; Stroke IL; Qin LY; Hussain Z; Simhadri S; Brescia MR; Waksmunski FS; Strohl B; Tellew JE; Williams JP; Saunders J; Appell KC; Henderson I; Webb ML
Bioorg Med Chem Lett; 2008 Oct; 18(20):5420-3. PubMed ID: 18815029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
